Gapping up
In reaction to earnings/guidance:
- ALV +8.1% (reaffirms outlook), LEN +3.9%
Other news:
- CNVY +138% (To Be Taken Private By TPG for $10.50 per share in cash)
- VALN +83.8% (Valneva SE and Pfizer (PFE) enter into an equity subscription agreement and update terms of collaboration agreement for VLA15)
- SAVE +8.8% (JetBlue (JBLU) submits proposal with increased offer of $33.50 per share in cash) K +8.4% (plans to separate into three independent companies)
- BNR +7.6% (announces $10 million share repurchase program)
- PAYA +7.1% (considering sale according to Bloomberg)
- EJFA +6.6% (shareholders approve proposed business combination with Pagaya Technologies; will trade on the Nasdaq under symbol "PGY")
- NRZ +5.3% (to change its name and rebrand as Rithm Capital (RITM); now operates as an internally managed REIT)
- SWN +5.2% (announces $1 billion share repurchase program)
- ABMD +5% (entered into a new 10b5-1 plan to continue repurchases of the Company's common stock under the Program)
- TRMR +4.7% (confirms that it is currently in discussions with Amobee alongside a number of ongoing strategic discussions with other third parties)
- IREN +4.3% (re-iterated expected total online operating capacity of 3.7 EH/s by the end of Q3 2022)
- EXAS +4.2% (entered a long-term supply agreement for Ultima's next-generation sequencing technologies)
- OCGN +3.7% (Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases)
- FANG +3.1% (announces further enhancement to its capital return program and intention to increase base dividend)
- STNG +3.1% (President of the Company and Scorpio Holdings Limited a related party have purchased common shares of the Company in the open marke)
- AZN +2% (Eplontersen met co-primary and secondary endpoints in interim analysis of the NEURO-TTRansform Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN))
- TWTR +1.7% (discloses that it recommends that shareholders vote for the adoption of the merger agreement)
- JBLU +1.4% (JetBlue (JBLU) submits proposal with increased offer of $33.50 per share in cash)
- ULCC +1.4% (JetBlue (JBLU) submits proposal with increased offer of $33.50 per share in cash)
- CRON +1.4% (Cronos Group and Ginkgo Bioworks (DNA) achieve THCV Equity Milestone; Cronos has issued to Ginkgo approximately 2.2 million common shares)
- MDLZ +1.2% (acquires Clif Bar & Company for $2.9 bln)
Analyst comments:
- CHWY +5.1% (upgraded to Outperform from Neutral at Wedbush)
- SU +4.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- PSO +4.8% (upgraded to Buy from Hold at Deutsche Bank)
- CUBE +3.7% (upgraded to Buy from Neutral at BofA Securities)
- SCHW +3.2% (upgraded to Buy from Neutral at UBS)
- FMC +3.1% (upgraded to Buy from Underperform at BofA Securities)
- XOM +2.6% (upgraded to Outperform from Neutral at Credit Suisse)
- CHD +2.4% (upgraded to Overweight from Equal Weight at Wells Fargo)
- AMT +2.2% (upgraded to Overweight from Underweight at JP Morgan)
- CNC +1.6% (upgraded to Outperform from Neutral at Credit Suisse)